ISPE Announces 2013 Board of Directors - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

ISPE Announces 2013 Board of Directors

ISPE has announced the results of its 2013-2014 International Board of Directors election. The Board will be responsible for the governance and strategic direction of the Society and will assume their elected positions at the 2013 ISPE Annual Meeting, Nov. 3–6 November in Washington, DC.

The following pharmaceutical industry leaders have been elected to positions on the 2013-2014 ISPE International Board of Directors:

• Chair: Damian Greene, Global Network Strategy Lead, Global Manufacturing and Supply, Zoetis
• Vice Chair: Andy Skibo, Regional Vice President, Biologics-Supply, MedImmune/AstraZeneca
• Treasurer: Joseph Famulare, Vice President – Global Compliance and External Collaboration, Genentech
• Secretary: Mike Arnold, RPh, Business Process Owner for Investigational Products and Senior Director of Strategic Partnerships, Global Clinical Supply Chain, Pfizer
• Past Chair: Charlotte Enghave Fruergaard, PhD, Partner, Global Consulting, NNE Pharmaplan 

Re-elected Directors
• James A. Breen, Jr., PE, LEED AP, Vice President, Worldwide Engineering and Technical Operations, Supply Chain Group, Johnson & Johnson
• Tim Howard, CPIP, PE, Vice President of Global Operations and Company Officer, Commissioning Agents, Inc. 

New Directors
• Mark Fitch, Senior Vice President of Global Operations, Impax Laboratories, Inc.
• Thomas Hartman, Vice President, GMP Operations, Biopharm CMC, GlaxoSmith Kline
• Robert “Bob” Matje, PE, CPIP, Senior Director of Engineering, Endo
• Christopher “Chris” Reid, CEO and Principal Consultant and Owner, Integrity Solutions Ltd.
• Fran Zipp (Sakers), Group Executive Vice President and Head of Quality Operations, Teva

In addition, Jennifer Lauria Clark, CPIP, Jim Durkin, and Gordon Leichter, PhD, who were elected in 2012 to serve a two-year term, will continue as directors.

Source: ISPE




blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here